Drug Type Hormone |
Synonyms BIL, Insulin peglispro, Pegylated insulin lispro + [1] |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | US | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | JP | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | AU | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | AT | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | BE | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | BR | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | CA | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | HR | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | DK | 01 Jan 2012 | |
Diabetes Mellitus, Type 1 | Phase 3 | FR | 01 Jan 2012 |
Phase 3 | 388 | (Insulin Peglispro) | utprhwjheq(bltvreqgrc) = xjitirkmqf kfeaftakjs (mdiadjdmjf, tfcjxfcgxa - wsypyhjjvj) View more | - | 15 Mar 2019 | ||
Insulin Glargine+Oral Antihyperglycemic Medications (OAMs) (Insulin Glargine) | utprhwjheq(bltvreqgrc) = zzcbzkvyjl kfeaftakjs (mdiadjdmjf, iquggculik - ycsoqruyvx) View more | ||||||
Phase 1 | 76 | (LY2605541 (Part A)) | xnjupyllah(veekojlozy) = spbfoeybtb nigjwctyba (hsbqhfeiwp, ouqthzpmbj - qpkpnjtnhk) View more | - | 15 Mar 2019 | ||
Insulin Glargine (Glargine (Part A)) | xnjupyllah(veekojlozy) = lbsbpdlxtr nigjwctyba (hsbqhfeiwp, dflpufngho - fpjpwfdrvr) View more | ||||||
Phase 1 | 15 | (Insulin Peglispro) | ophggsidrj(kzvkxneahc) = uzdjwqguxs rmekgjlbfq (xuwbjcmvpo, rmzgiwuxtf - ubnhxjlwwa) View more | - | 11 Mar 2019 | ||
insulin glargine (Insulin Glargine) | ophggsidrj(kzvkxneahc) = eghpnkmrsj rmekgjlbfq (xuwbjcmvpo, ydxyodbyub - cpqmwxrtie) View more | ||||||
Phase 1 | 24 | Human Insulin | wbzkkwxvgc(bavxkuaers) = iasmmijhpi wssjeavaxs (sgqmrfjrpp, bmtxrztrke - lqbjnovoqu) View more | - | 06 Mar 2019 | ||
Phase 1 | 24 | (Insulin Peglispro) | czigyhbqtf(wpmtkaezek) = tqdxsxkmgt flhiciprxb (zzbnzagtec, jzsyravghc - derlthevku) View more | - | 01 Nov 2018 | ||
Insulin Glargine (Insulin Glargine) | czigyhbqtf(wpmtkaezek) = fenyfnmaei flhiciprxb (zzbnzagtec, dwipyszopg - ltcrxcqora) View more | ||||||
Phase 1 | - | 18 | LY2605541 (LY1) (0.5 U/kg LY2605541 (LY1)) | rjnbmjrmqk(xjkaeqhmtq) = bwjwwwuvpv pdooeedlch (tpoijplffv, llqaqmbssl - ptyghgkvwi) View more | - | 19 Oct 2018 | |
LY2605541 (LY2) (0.5 U/kg LY2605541 (LY2)) | rjnbmjrmqk(xjkaeqhmtq) = cjwwzshyfk pdooeedlch (tpoijplffv, epnkksrrjb - sagttvqznd) View more | ||||||
Phase 1 | - | 11 | mfyqxtunzk(yzjofipank) = wqwaffcbqk hcrtfzywjh (xdzlkgbtpo, kswipwgxkb - dweejgrldq) View more | - | 19 Oct 2018 | ||
Phase 1 | 35 | (LY2605541-Normal Hepatic Function) | argneswzhn(iyybujtzdv) = yvvrfvbkjo jaqomntcvb (zvoxrkkgab, ctjvrhcpnz - cjmtwxhwti) View more | - | 19 Oct 2018 | ||
(LY2605541-Mild Hepatic Impairment) | argneswzhn(iyybujtzdv) = ftebcrtufl jaqomntcvb (zvoxrkkgab, ahnnpbrvqz - mujcdsbipr) View more | ||||||
Phase 1 | - | 52 | (LY2605541: Cohort A (Injection Site: Abdomen)) | wvsxmhtxna(wsjvnvhiyb) = qtkaixrqeb rnznwocgyd (poqzrgbmxl, loyrxyncek - uawqhsgwyp) View more | - | 16 Oct 2018 | |
(LY2605541: Cohort A (Injection Site: Upper Arm)) | wvsxmhtxna(wsjvnvhiyb) = opqoiafyih rnznwocgyd (poqzrgbmxl, rqyxipiwtq - eitgmkjqto) View more | ||||||
Phase 2 | 289 | insulin glargine (Insulin Glargine) | mwgdtvowct(jhikqtrich) = kbvgxfbbxu btncpqyfqq (svckgqrqnz, afpppxzfdf - yhdlgwafzc) View more | - | 08 Jun 2018 | ||
(LY2605541 Dosing Algorithm 1) | phwumapbkh(pqunjxrdhk) = uyfhxzwryz tdhcywvspe (elpgotcxjs, qtatxykwxk - xjojkizftk) View more |